SeaSpine (SPNE) and Atossa Genetics (ATOS) Head-To-Head Contrast

SeaSpine (NASDAQ: SPNE) and Atossa Genetics (NASDAQ:ATOS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends and valuation.

Institutional and Insider Ownership

46.1% of SeaSpine shares are owned by institutional investors. Comparatively, 48.7% of Atossa Genetics shares are owned by institutional investors. 13.5% of SeaSpine shares are owned by insiders. Comparatively, 5.6% of Atossa Genetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares SeaSpine and Atossa Genetics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
SeaSpine -21.75% -27.65% -21.65%
Atossa Genetics N/A -186.36% -145.47%

Risk & Volatility

SeaSpine has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500. Comparatively, Atossa Genetics has a beta of 3.35, meaning that its stock price is 235% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for SeaSpine and Atossa Genetics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SeaSpine 0 0 5 0 3.00
Atossa Genetics 0 0 1 0 3.00

SeaSpine presently has a consensus target price of $18.00, suggesting a potential upside of 29.50%. Atossa Genetics has a consensus target price of $10.00, suggesting a potential upside of 338.60%. Given Atossa Genetics’ higher possible upside, analysts clearly believe Atossa Genetics is more favorable than SeaSpine.

Earnings and Valuation

This table compares SeaSpine and Atossa Genetics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SeaSpine $131.81 million 1.55 -$32.11 million ($2.58) -5.39
Atossa Genetics N/A N/A -$8.12 million N/A N/A

Atossa Genetics has lower revenue, but higher earnings than SeaSpine.

About SeaSpine

SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. The company provides orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical regions of the spine. Its orthobiologics products include demineralized bone matrices, collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to enhance bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures. The company offers orthobiologics products in various forms, such as putties, pastes, strips, and resorbable mesh. Its spinal implant portfolio comprises products for spinal decompression, alignment, and stabilization that are used to facilitate fusion in minimally invasive, complex, deformity, and degenerative procedures. The company was incorporated in 2015 and is headquartered in Carlsbad, California.

About Atossa Genetics

Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid (NAF)for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as manufactures and sells various medical devices primarily consisting of tools to assist breast surgeons. Atossa Genetics Inc. was founded in 2009 and is headquartered in Seattle, Washington.

Receive News & Ratings for SeaSpine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SeaSpine and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit